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THE BLURRED DISTINCTION
BETWEEN TREATABLE AND
UNTREATABLE CONDITIONS IN
NEWBORN SCREENING
Donald B. Bailey, Jr.t
ABSTRACT
Newborn screening is increasingly possible for conditions that do
not have medical treatments that must be provided early in order to be
effective. This raises a fundamental question of what information
should be disclosed to parents. Historically the potential for treatment
has been essential before conditions are included in newborn screen-
ing. Here I argue that the distinction between treatable and untreat-
able conditions is not a clear one and may be less useful in the future.
I give examples of treatments that could be used even with "untreat-
able" conditions, envision a possible future of newborn screening, and
suggest research and policy questions that need to be answered
quickly so that screening can expand in a rational fashion.
THE BLURRED DISTINCTION BETWEEN
TREATABLE AND UNTREATABLE CONDITIONS IN
NEWBORN SCREENING
Newborn screening was established in the 1970s in the United
States when a screening test and an effective treatment became avail-
able for phenylketonuria (PKU). By altering an infant's diet, the in-
tellectual disability and other developmental problems associated with
PKU could be prevented. Since the effects of PKU were irreversible,
the treatment had to be provided early in life in order to be effective.
This fundamental expectation - that screening should be justified by
the need for a known medical treatment that had to be provided early
1 Preparation of this article was supported in part by grants from the Ethical,
Legal, and Social Implications Research Program, National Human Genome Research
Institute (Grant number 1P50-HG004488) and the National Institute for Child Health
and Human Development (Grant number R21-HD043616).
I Distinguished Fellow, RTI (Research Triangle Institute) International.
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in life to be effective - has served as the foundation for what is now a
well-established newborn screening program in every state, the goal
of which is to identify, shortly after birth, children with conditions in
need of immediate treatment.
However, as technology advances and large-scale genetic testing
becomes cheaper, new methodologies for detecting conditions will
increasingly be capable of simultaneously identifying a large number
of conditions, disease states, or risk states that may not have medical
treatments currently available. This phenomenon is already a reality
in the case of tandem mass spectrometry, 2 a methodology now widely
used by newborn screening programs to identify multiple conditions
at the same time, and will only grow as technology moves toward
microarray or whole-genome analyses. Inevitably this will pose a
dilemma regarding the disclosure of results, as articulated by Botkin
et al.:
If programs choose only to disclose results on conditions that
clearly meet established criteria, then results on the other con-
ditions, and the potential benefits flowing from those results,
will be withheld from families and care providers. On the
other hand, offering results on a large number of conditions
for which there is limited or no evidence of benefit to affected
children may cause harm to some children and families and is
likely to be a poor use of scarce resources.4
In this article, I continue our examination of changing perspec-
tives on the definition of treatment, concepts of benefit, and the stan-
dards of evidence needed before a condition is included in newborn
screening programs. I suggest that differentiating between treatable
2 Dietrich Matern, Piero Rinaldo, & Silvia Tortorelli, Newborn Screening:
Opportunities and Challenges of Tandem Mass Spectrometry, CLINICAL LABORATORY
NEWS, Aug. 2003, at 12-15.
3 Joseph G. Hacia & Francis S. Collins, Mutational Analysis Using
Oligonucleotide Microarrays, 36 J. MED. GENETICS 730 (1999).
4 Jeffery R. Botkin et al., Newborn Screening Technology: Proceed with
Caution, 117 PEDIATRICS 1793, 1796 (2006).
5 Don Bailey, Newborn Screening for Intellectual Disability: Past, Present,
and Future, in 36 INTERNATIONAL REVIEW OF RESEARCH IN MENTAL RETARDATION 1
(Laraine Masters Glidden ed., 2008); Donald B. Bailey, Jr., Newborn Screening for
Fragile X Syndrome, 10 MENTAL RETARDATION & DEVELOPMENTAL DISABILITIES
RES. REVIEWS 3 (2004); Donald B. Bailey, Jr. et al., Supporting Family Adaptation to
Presymptomatic and "Untreatable" Conditions in an Era of Expanded Newborn
Screening, 33 J. PEDIATRIC PSYCHOL. 1 (2008); Donald B. Bailey, Jr. et al., Changing
Perspectives on the Benefits of Newborn Screening, 12 MENTAL RETARDATION &
DEVELOPMENTAL DISABILITIES RES. REVIEWS 270 (2006); Donald B. Bailey et al.,
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and untreatable conditions is a dichotomy that will become less useful
and less clear in the next generation of newborn screening and genetic
testing more broadly. I give examples of four "treatments" that could
be used even with "untreatable" conditions. The paper concludes with
a set of questions that need to be answered to help inform debates
about treatability and benefit.
I. CURRENT CONCEPTS OF TREATMENT AND
BENEFIT
Most states currently screen for at least a core set of 29 conditions
recommended by a 2006 report developed under the auspice of the
American College of Medical Genetics (ACMG).6 The ACMG report
resulted from an extensive deliberation by experts to create a system
for scoring diseases or conditions with regard to suitability for new-
born screening. Following a rating of more than 80 conditions by
experts, ACMG recommended that all states screen for the core condi-
tions and report out 25 additional conditions that would necessarily be
identified when testing for the core conditions, even though treatments
are not available for all. The report has been enormously influential,
as evidenced by the rapid increase in the number of conditions
screened since the report was released. The current status of newborn
screening in each state is available at http://genes-r-
us.uthscsa.edu/nbsdisorders.pdf.
Treatment and benefit figured prominently into the scoring sys-
tem. Of the possible total of 2100 points, 600 could be earned for the
potential efficacy of existing treatments (200), benefit of early inter-
vention to individuals (200), benefit of early identification for family
and society (100), and the prevention of mortality (100). Another 400
points could be assigned based on treatment availability, cost, simplic-
ity of therapy, and availability of providers to implement the treat-
ments.
Although the 29 core conditions all have treatments that either
prevent death or improve health outcomes, there was a continuum of
expert opinion regarding treatment efficacy for each, as evidenced in
Figure 1. The figure depicts for each condition the percent of the
maximum score that would have been received had all experts agreed
Ethical, Legal, and Social Concerns About Expanded Newborn Screening: Fragile X
Syndrome as a Prototype for Emerging Issues, 121 PEDIATRICS e693 (2008); Donald
B. Bailey, et al., Newborn Screening for Developmental Disabilities: Refraining Pre-
sumptive Benefit, 95 AM. J. Pun. HEALTH 1889 (2005).
6 Michael S. Watson et al., Newborn Screening: Toward a Uniform Screen-
ing Panel and System, 8 GENETIcs MED. (SUPP.) 1 S (2006).
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that the treatment could prevent all negative consequences of the con-
dition. The ratings ranged from 32% - 85%.
Only four conditions (congenital hypothyroidism, biotinidase
deficiency, PKU, and medium chain- acyl-CoA dehydrogenase or
MCAD) were rated as having treatments that prevent all negative con-
sequences. For example, MCAD is an autosomal recessive disorder,
inherited when both parents carry the abnormal MCAD gene.
Children with MCAD have a missing or faulty enzyme needed to
break down fat. This only becomes a problem, however, if children
go without food for more than 10-12 hours. A child with MCAD
could look perfectly normal for months, but then develop severe
symptoms during the course of an illness such as the flu, when the
child may not feel like eating. If not treated quickly, the child can
have seizures or die. The primary treatment regimen involves careful
monitoring of diet and avoiding fasting. L-camitine is prescribed to
prevent low blood sugar when children have other illnesses. If these
procedures are followed, children with MCAD are expected to have
normal growth and development.7
However, more than half of the recommended panel of core
conditions and most of the secondary targets were considered to have
treatments that only prevent "some" of the negative consequences of
8the condition. For example, every state requires or offers screening
for propionic acidemia, a rare inherited disorder that affects the
body's ability to break down certain proteins, leading to the buildup of
harmful substances in blood and urine. Untreated propionic acidemia
can lead to severe neurological damage, coma and death. Treatment
usually involves a combination of a low-protein diet, medication
treatment, and monitoring to make sure that children eat something
every 4-6 hours to prevent a metabolic crisis. Although early treat-
ment significantly reduces mortality and improves health outcomes,
children with propionic acidemia typically have a range of health
problems, sometimes severe, throughout life.9
7 Gabriella A. Horvath et al., Newborn Screening for MCAD Deficiency:
Experience of the First Three Years in British Columbia, Canada, 99 CAN.J. PUB.
HEALTH 276 (2008).
8 Donald B. Bailey, Jr. et al., Changing Perspectives on the Benefits of
Newborn Screening, 12 MENTAL RETARDATION & DEVELOPMENTAL DISABILITIES REs.
REVIEWs 270 (2006).
9 Carlo Dionisi-Vici et al., 'Classical' Organic Acidurias, Propionic
Aciduria, Methylmalonic Aciduria and Isovaleric Aciduria: Long-Term Outcome and
Effects of Expanded Newborn Screening Using Tandem Mass Spectrometry, 29 J.
INHERITED METABOLIC DISEASE 383 (2006).
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Although the ACMG report has had a major influence on state
policy and practice, it has been criticized for both its methodology and
some of its recommendations. Some have expressed concern that the
report sets a new precedent by recommending screening for some
conditions without sufficient research evidence regarding treatment
efficacy and by using new criteria (benefit to family and society) that
have not previously been considered in making screening decisions.' 0
These are valid points. The report was not a research review per se
and for some conditions there simply have not been adequate longitu-
dinal studies with sufficiently large samples to fully understand the
long-term consequences of screening and treatment. Since most of
the conditions screened are rare, a national program of coordinated
research is clearly needed to answer questions about the real benefits
of specific treatments and whether other ethical, legal, and social con-
cerns are valid."
In the meantime, technology is developing at a rapid pace. Advo-
cacy groups continue to push for expanded screening 12 and private
companies are offering supplementary screening options to families
who can afford it. What will be the role of treatability and proven
treatment efficacy in this rapidly changing context? What would be
the advantages and disadvantages of expanding concept of benefit
beyond child health? Would such expansion be welcomed by the
public and lead to improved outcomes for children and families, or
would it overburden an already stretched system and not achieve the
hoped-for benefits?
II. EXPANDING THE RANGE OF POTENTIAL
BENEFITS FROM NEWBORN SCREENING
Baily and Murray 13 argue that newborn screening must be evi-
denced-based to be ethical, a position generally consistent with virtu-
ally all analyses of newborn screening. But sometimes this evidence
10 Jeffery R. Botkin et al., Newborn Screening Technology: Proceed with
Caution, 117 PEDIATRICS 1793 (2006); Marvin Natowicz, Newborn Screening -
Setting Evidence-Based Policy for Protection, 353 NEwENG. J. MED. 867 (2005).
11 Donald B. Bailey et al., Ethical, Legal, and Social Concerns About
Expanded Newborn Screening: Fragile X Syndrome as a Prototype for Emerging
Issues, 121 PEDIATRICS e693 (2008).
12 Diane B. Paul, Patient Advocacy in Newborn Screening: Continuities and
Discontinuities, 148 AM. J. OF MED. GENETICS PART C (SEMINARS IN MEDICAL
GENETICS) 8 (2008).
13 Mary Ann Baily & Thomas H. Murray, Ethics, Evidence, and Cost in
Newborn Screening: Would Resources Spent on Screening be Better Spent Else-
where?, 38 HASTINGS CENTER REP. 23 (2008).
20091
HEALTH MATRIX
can take a long time to develop and it may be virtually impossible to
meet some standards of evidence (e.g., multiple random
assignment studies, placebo or no-treatment conditions for rare condi-
tions that are life-threatening, longitudinal follow-up studies). An
example of the dilemmas created by the expectation for evidenced-
based decision-making is newborn hearing screening. In 2001 the
U.S. Preventive Services Task Force reported that there was insuffi-
cient evidence of the efficacy of newborn hearing screening. None-
theless, advocacy groups continued to push for screening and as a
result all states now require or offer newborn hearing screening. A
recent update of the task force statement 14 still only gave newborn
screening a grade of "B" and concluded that "there is moderate cer-
tainty that the net benefit of screening all newborn infants for hearing
loss is moderate."' 5
Data from the ACMG report help draw a distinction between
treatment and benefit. Treatment refers to the intervention that is pro-
vided, whereas benefit refers to the results obtained when the treat-
ment is provided. It could be argued that the primary standard for
newborn screening should not be whether a treatment is available, but
rather whether benefit accrues as a result of early identification.
Newborn screening should not be conducted if no benefit is antici-
pated. But what is meant by meaningful benefit and what types of
benefit would be considered valid?
The US Preventive Services Task Force emphasizes improved
health as the benchmark outcome. But medical treatment of a condi-
tion is only one of a number of potential benefits of newborn screen-
ing.1 6  The history of newborn hearing screening and more recent
findings 17 show that parents, advocacy groups, and some clinicians
often perceive a wider range of benefits than traditionally consid-
ered. 8
14 US Preventive Services Task Force, Universal Screening for Hearing Loss
in Newborns: US Preventive Services Task Force Recommendation Statement, 122
PEDIATRICS 143 (2008).
15 Id. at 144.
16 Donald B. Bailey, et al., Newborn Screening for Developmental Disabili-
ties: Refraining Presumptive Benefit, 95 AM. J. PUB. HEALTH 1889 (2005).
17 Donald B. Bailey, Jr. et al., Changing Perspectives on the Benefits of
Newborn Screening, 12 MENTAL RETARDATION & DEVELOPMENTAL DISABILITIES RES.
REviEws 270 (2006).
18 Diane B. Paul, Patient Advocacy in Newborn Screening: Continuities and
Discontinuities, 148 AM. J. OF MED. GENETICS PART C (SEMINARS IN MEDICAL
GENETICS) 8 (2008); Debra Skinner et al., Screening for Fragile X Syndrome: Parent
Attitudes and Perspectives, 5 GENETICS MED.378 (2003).
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Figure 2 provides some examples of an expanded set of goals for
newborn screening that could result in a wide range of benefits for
children, families, and society. For children, the benefits could extend
beyond reducing mortality and improving physical health. Early
intervention could help prevent secondary conditions, enhance devel-
opmental outcomes, promote positive emotional development and
adaptation, and maximize quality of life. For families, the benefits
could include access to potentially important health information, the
avoidance of the financial and emotional costs of a lengthy quest to
find out what is wrong with their child, and empowerment to advocate
more effectively for appropriate services for their child. For heritable
disorders, newborn screening would provide timely information about
reproductive risks for the parents as well as for extended family mem-
bers who might also be carriers of the condition. From a societal per-
spective, newborn screening, even for "untreatable conditions," could
help assure that all families have equitable access to timely health
information, that public health services minimize costs and maximize
benefits, and that the adverse consequences to society of the lack of
universally available health care information are avoided.
How these benefits are considered when evaluating the suitability
of conditions for screening is an issue yet to be resolved.' 9 Whether
this shift would be desirable or not is currently debated. At the end of
this paper, I suggest some questions that need to be answered in order
to inform this discussion.
III. REVISITING TREATMENTS AND TREATMENT
OUTCOMES
A recent report from a national newborn screening advisory
committee20 described four components that would be an essential
part of any treatment program: coordinated care through a medical
home, evidenced-based treatment, ongoing quality assessment and
improvement, and research to discover new knowledge about the con-
ditions screened. Providing even these core components is currently
19 Beth A. Tarini, The Current Revolution in Newborn Screening: New Tech-
nology, Old Controversies, 161 ARCHIVES OF PEDIATRIC AND ADOLESCENT MED. 767,
769 (2007) (characterizing efforts to expand concepts of benefit as "a
radical shift from the traditional goals of screening").
20 Alex R. Kemper et al., Long-Term Follow-Up After Diagnosis Resulting
from Newborn Screening: Statement of the U.S. Secretary of Health and Human
Services' Advisory Committee on Heritable Disorders and Genetic Diseases in New-
borns and Children, 10 GENETICS MED. 259 (2008).
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challenging, and efforts are needed to standardize more broadly the
principles recommended in this report.
In a recent paper, we expand the concept of follow-up by sug-
gesting four treatments that could be provided for "untreatable" condi-
tions: information, support, surveillance, and intervention. Here I
suggest outcomes that could be measured as a result of these treat-
ments.
Information. Newborn screening results in a laboratory report
providing information about genetic or metabolic abnormalities. But
this report is usually only the first step in a family's quest to under-
stand what the condition is and what it means for their child. Often
this involves learning a new vocabulary, meeting new professionals,
learning about basic biological processes, and understanding both the
certainties and uncertainties associated with a diagnosis. For many
parents this information will be confusing and overwhelming, and
could lead to misunderstanding, anxiety, or despair. To prevent this
from happening, families need to have access to accurate and under-
standable information. This "treatment" could include brochures,
web-based resources, and access to knowledgeable and sensitive
professionals. Multiple sources of information should be available in
multiple languages. The materials should address common questions
that parents have and promote hope and optimism. If families have
access to accurate and understandable information, the ultimate bene-
fit will be that families are empowered as participants in informed
decision-making.
Support. To deal with complicated genetic information and the
challenges inherent in raising a child with a condition that may affect
health and development, families need to have emotional and func-
tional assistance from a trusted source. Professionals can provide this
when they use family-centered practices that respect family beliefs,
values and goals, promote parent-professional collaboration, and
focus on a positive outlook and quality of life issues. Also important
are the informal support networks - friends and neighbors, religious
or community organizations, support groups or parent-to-parent
programs, and even virtual communities formed on the internet.
When families have emotional and functional assistance from a
trusted source, the ultimate benefit will be that families feel supported
by professionals and a social network, are optimistic about the future,
21 Donald B. Bailey, Jr. et al., Supporting Family Adaptation to Presympto-
matic and "Untreatable " Conditions in an Era of Expanded Newborn Screening, 33
J. PEDIATRIC PSYCHOL. 1 (2008).
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and are able to cope with both the adversities and uncertainties associ-
ated with their child's condition.
Surveillance. An important component of follow-up is surveil-
lance, in which children participate in periodic screenings or assess-
ments. These could include systematic use of standardized screening
tools and clinical observations informed by knowledge of the condi-
tion and the range of possible secondary complications. Parent obser-
vations and reports should be valued and included as part of the ongo-
ing assessment. When children participate in appropriate and periodic
screening or assessments, the ultimate benefit will be that parents are
reassured that someone is paying attention to their child's well-being
so that services or treatments will start promptly when needed.
Intervention. Treatments and services have historically been key
to newborn screening follow-up. Here we refer both to medical
treatments as well as non-medical treatments, such as early interven-
tion programs, parent training, and specialized services such as occu-
pational therapy or speech-language therapy. These treatments or
services should be based on assessed needs and individualized. A
team approach should maximize integration of goals and services,
fitting treatments into family routines and maximizing children's par-
ticipation in family and community. When children and families
receive a wide range of individualized treatments and services, the
ultimate benefit is that health, development, and quality of life are
maximized, and the primary or secondary consequences of conditions
are minimized.
IV. SUMMARY AND FUTURE DIRECTIONS
What will be the future of newborn screening and what will be the
role of concepts such as treatment and benefit? In Figure 4, I suggest
one envisioned future of newborn screening, contrasted with current
screening programs. Currently, most newborn screening is not volun-
tary, rather it is a mandated public health program with limited op-
tions for non-participation. Parents are generally told about the pro-
gram during prenatal visits and get written information about screen-
ing in the packet of materials they receive in the hospital, but mostly
this is for their information only. States screen for anywhere from 25
to 55 conditions based on state policy and medical need. Follow-up
typically consists of medical management, either by the child's
primary physician or a regional disease specialist. These programs
are typically evaluated with regard to reductions in morbidity and
mortality, and cost effectiveness.
In the near future, perhaps the next 3-5 years, we can expect a
number of possible changes in screening. There will likely be a selec-
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tive expansion of screening as more genes or other biomarkers are
discovered or new treatments are developed. Some of these may be
offered in the context of voluntary programs with informed consent.
As technology continues to develop, the likelihood of "secondary
targets" will grow, which refers to conditions that were not the
original target of a laboratory test but which are necessarily identified
secondary to the primary intent of screening. There will be increasing
pressure to disclose these results but the benefit of doing so will be
unclear. Hopefully we will see collaboration between the medical
management of identified children and other service systems such as
early intervention community programs. I predict that we will see a
gradual yet consistent shift in the evaluation of newborn screening,
with well-being and benefit defined more broadly and the ability to
help families adapt successfully to information from screening being
one criterion for determining the desirability of screening.
In the next decade, I foresee a radical shift in both the possibilities
and complexities of newborn screening. New technologies will make
whole-genome scans increasingly likely and affordable, opening up
the possibility of detecting hundreds of pieces of health-related infor-
mation at birth. This will force a radical re-examination of the pur-
pose and form of newborn screening, potentially leading to a new
integration of medicine and public health.22  Informed decision-
making strategies will be needed to help families know about these
possibilities well before birth so that they can make informed deci-
sions about whether and what information they would like. This will
require a re-designed system of comprehensive, coordinated and fam-
ily-centered services. Evaluation issues will become increasingly
complex, and there may be a paradigm shift in expectations for evi-
dence.
If this is a possible future for newborn screening, research and
thoughtful policy discussions will be needed to make sure that we
understand the ramifications of possible changes and how to prepare
for them. Some questions that should be addressed include:
* If the cost of screening becomes irrelevant (or less relevant) or
technology evolves toward whole genome screening possibili-
ties, what role will treatment potential play in decisions about
the disclosure of results?
22 Scott D. Grosse et al., From Public Health Emergency to Public Health
Service: The Implications of Evolving Criteria for Newborn Screening Panels, 117
PEDIATRICS 923 (2006); Muin J. Khoury et al., Will Genomics Widen or Help Heal
the Schism Between Medicine and Public Health?, 33 AM. J. OF PREVENTIVE MED.
310 (2007); Muin J. Khoury et al., Quantifying the Health Benefits of Genetic Tests:
The Importance of a Population Perspective, 8 GENETICS MED. 191 (2006).
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* How important is treatability of a condition from the perspec-
tive of consumers, the parents who would be the recipients of
health-related information?
* Would a two-tier system of screening, with some conditions
being mandated and others voluntary, be possible or desirable,
and how would treatment potential figure in determining
which conditions go into which tiers?
" Are there ways to quantify expanded benefits to the child,
family, or society so that cost-benefit analyses are possible?
" What systematic research is needed to assure that the debate
over treatability of conditions is, itself, evidenced-based?
Answering these questions earlier rather than later will help assure
that decisions with regard to expansion of newborn screening are
adequately informed.
Figure 1. Percent of maximum score rating for efficacy of treat-
ments available for the 29 core conditions recommended by the
American College of Medical Genetics (Data compiled from tables
provided in Watson et al., 2006).
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Figure 2. Child, family, and societal goals of newborn screening
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Figure 3. Four types of treatment and their consequences.
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